# Lumos Pharma Inc. (LUMO)

Source: https://www.quantisnow.com/company/LUMO
Generated: 2026-11-22T06:19:28.944Z

- Ticker: LUMO
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2011
- Website: lumos-pharma.com

## About

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.

## Latest LUMO news and filings

- 2025-04-09 11:00 UTC [Leadership Update] [Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors](https://www.quantisnow.com/insight/aviceda-therapeutics-appoints-ophthalmology-innovator-and-industry-leader-dr-emmett-5982114)
- 2024-12-23 13:00 UTC [SEC Form 15-12G filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-lumos-pharma-inc-5823240)
- 2024-12-14 02:32 UTC [SEC Form 4] [Chief Executive Officer Hawkins Richard J returned 757,562 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-hawkins-richard-j-returned-757562-shares-to-5813763)
- 2024-12-14 02:32 UTC [SEC Form 4] [Director Zoth Lota S. returned 2,187 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-zoth-lota-s-returned-2187-shares-to-the-company-5813762)
- 2024-12-14 02:32 UTC [SEC Form 4] [Chief Scientific Officer Mckew John C. returned 13,153 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-mckew-john-c-returned-13153-shares-to-5813761)
- 2024-12-14 02:32 UTC [SEC Form 4] [Director Johnson Chad Allen returned 1,076 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-johnson-chad-allen-returned-1076-shares-to-the-company-5813760)
- 2024-12-14 02:31 UTC [SEC Form 4] [Director Van Es-Johansson An returned 1,100 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-van-es-johansson-an-returned-1100-shares-to-the-company-5813759)
- 2024-12-14 02:31 UTC [SEC Form 4] [Director Raffin Thomas A. returned 9,406 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-raffin-thomas-a-returned-9406-shares-to-the-company-5813758)
- 2024-12-14 02:31 UTC [SEC Form 4] [Chief Medical Officer Pitukcheewanont Pisit Duke returned 16,836 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-pitukcheewanont-pisit-duke-returned-16836-shares-to-5813757)
- 2024-12-14 02:31 UTC [SEC Form 4] [Director Lalande Kevin M. returned 731,522 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-lalande-kevin-m-returned-731522-shares-to-the-company-5813756)
- 2024-12-14 02:31 UTC [SEC Form 4] [Chief Business Officer Schuchart Aaron returned 8,179 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-business-officer-schuchart-aaron-returned-8179-shares-to-the-5813755)
- 2024-12-14 02:30 UTC [SEC Form 4] [General Counsel Powers Bradley J returned 6,334 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/general-counsel-powers-bradley-j-returned-6334-shares-to-the-5813754)
- 2024-12-14 02:30 UTC [SEC Form 4] [Director Mccracken Joseph S returned 15,721 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-mccracken-joseph-s-returned-15721-shares-to-the-company-5813753)
- 2024-12-14 02:30 UTC [SEC Form 4] [Chief Financial Officer Lawley Lori D returned 12,284 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-lawley-lori-d-returned-12284-shares-to-5813752)
- 2024-12-13 13:10 UTC [SEC Form AW filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-aw-filed-by-lumos-pharma-inc-5812320)
- 2024-12-13 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-lumos-pharma-inc-5812142)
- 2024-12-13 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-lumos-pharma-inc-5812139)
- 2024-12-13 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-lumos-pharma-inc-5812130)
- 2024-12-13 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-lumos-pharma-inc-5812125)
- 2024-12-13 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-lumos-pharma-inc-5812117)
- 2024-12-12 16:05 UTC [SEC Form POS AM filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-lumos-pharma-inc-5810792)
- 2024-12-12 16:03 UTC [SEC Form POS AM filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-lumos-pharma-inc-5810791)
- 2024-12-12 16:01 UTC [SEC Form POS AM filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-lumos-pharma-inc-5810787)
- 2024-12-12 15:59 UTC [SEC Form POS AM filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-lumos-pharma-inc-5810782)
- 2024-12-12 15:56 UTC [SEC Form POS AM filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-lumos-pharma-inc-5810781)
- 2024-12-12 15:54 UTC [SEC Form POS AM filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-lumos-pharma-inc-5810777)
- 2024-12-12 15:51 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-lumos-pharma-inc-5810773)
- 2024-12-12 15:49 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-lumos-pharma-inc-5810772)
- 2024-12-12 15:47 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-lumos-pharma-inc-5810771)
- 2024-12-12 15:45 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-lumos-pharma-inc-5810770)
- 2024-12-12 15:43 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-lumos-pharma-inc-5810769)
- 2024-12-12 15:41 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-lumos-pharma-inc-5810768)
- 2024-12-12 15:39 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-lumos-pharma-inc-5810765)
- 2024-12-12 15:28 UTC [SEC Form 8-K] [Lumos Pharma Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year](https://www.quantisnow.com/insight/lumos-pharma-inc-filed-sec-form-8-k-completion-of-acquisition-5810759)
- 2024-12-12 14:42 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-lumos-pharma-inc-5810727)
- 2024-12-12 13:47 UTC [Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma](https://www.quantisnow.com/insight/lumos-pharma-and-double-point-ventures-announce-successful-completion-of-5810607)
- 2024-11-29 22:09 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-lumos-pharma-inc-5794817)
- 2024-11-25 11:02 UTC [SEC Form 8-K] [Lumos Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/lumos-pharma-inc-filed-sec-form-8-k-notice-of-delisting-5789295)
- 2024-11-21 14:00 UTC [Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201's Unique Pulsatile Mechanism of Action](https://www.quantisnow.com/insight/updated-phase-2-oragrowth-data-presented-at-espe-2024-demonstrate-5786238)
- 2024-11-14 14:04 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9 filed by Lumos Pharma Inc.](https://www.quantisnow.com/insight/sec-form-sc-14d9-filed-by-lumos-pharma-inc-5773676)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/LUMO
- Earnings history: https://www.quantisnow.com/earnings/LUMO
- Dividend history: https://www.quantisnow.com/dividends/LUMO
- Insider transactions: https://www.quantisnow.com/insiders/LUMO
- Options chain: https://www.quantisnow.com/options/LUMO
- SEC 8-K filings only: https://www.quantisnow.com/company/LUMO/8-k
- RSS and alerts for LUMO: https://www.quantisnow.com/docs/rss-feeds.md
